R&D Trends

Baxalta, Precision BioSciences ink $1.6B immuno-oncology collaboration

Friday, February 26, 2016

Baxalta, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, a genome editing company, have announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers.

[Read More]

CHOP, Seven Bridges form Cavatica for pediatric cancer genomics data

Friday, February 26, 2016

The Children’s Hospital of Philadelphia (CHOP), the lead operations center for the Childhood Brain Tumor Tissue Consortium (CBTTC), and Seven Bridges, a biomedical data analysis company, have announced the joint development of Cavatica, a new cloud-based environment for securely storing, sharing and analyzing large volumes of pediatric cancer patient genomics data. Cavatica will support CHOP’s commitment to the White House Precision Medicine Initiative (PMI) through the newly launched Center for Data Driven Discovery in Biomedicine (D3b), located at CHOP. 

[Read More]

Gilead launches HIV cure grants program

Tuesday, February 23, 2016

Gilead Sciences will be providing grants for up to three years to academic institutions, nonprofit organizations and community groups engaged in HIV cure activities. The unrestricted grants will be awarded to organizations with a track record of excellence in results-driven research.

[Read More]

Bristol-Myers Squibb, Dana-Farber partner on immuno-oncology research program

Tuesday, February 16, 2016

Bristol-Myers Squibb and Dana-Farber Cancer Institute have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. Dana-Farber Cancer Institute is the latest academic-based cancer center to join the I-O RPM program, which is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

[Read More]

AstraZeneca, MedImmune join chronic kidney disease consortium

Friday, February 12, 2016

AstraZeneca and its global biologics research and development arm MedImmune have entered into a collaboration with the University of Michigan and Eli Lilly to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD). The RPC2 consortium (renal precompetitive consortium) will combine extensive clinical and molecular data collected by Professor Matthias Kretzler at the University of Michigan with the R&D expertise of the pharmaceutical industry.

[Read More]

Biogen joins Center for Therapeutic Target Validation

Wednesday, February 10, 2016

Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.

[Read More]

FDA seeks $5.1B for FY 2017

Wednesday, February 10, 2016

The FDA is requesting a total budget of $5.1 billion to protect and promote the public health as part of the President’s fiscal year (FY) 2017 budget—an 8% increase over the enacted budget for FY 2016. The overall request includes a net increase of $14.6 million in budget authority and $268.7 million in user fees for initiatives tied to several key areas, including the implementation of the FDA Food Safety Modernization Act (FMSA) and efforts to improve medical product safety and quality. The agency is also seeking $75 million in new mandatory funding to support the National Cancer Moonshot initiative being led by the vice president.

[Read More]

RCPCH launches a Children’s Health Research Capacity Development Fund

Tuesday, February 9, 2016

Substantial advances have been made over the last decade in preventing and treating disease, but discovery science and biomedical research, essential for the advancement of medicine, remain disproportionately focused upon adult conditions. This has prompted the Royal College of Pediatrics and Child Health (RCPCH) to launch a Children’s Health Research Capacity Development Fund to support a growth in the number of child health researchers in the U.K. and abroad.

[Read More]

EMA sets up task force on Zika virus

Tuesday, February 9, 2016

The EMA has established a task force of European experts with specialized knowledge in vaccines, infectious diseases and other relevant expertise to contribute to the global response to the threat of the Zika virus infection. This group will be available to give advice on any scientific and regulatory matters for the research and development of medicines or vaccines against the virus.

[Read More]